25.62
-0.61(-2.33%)
Currency In USD
| Previous Close | 26.23 |
| Open | 25.85 |
| Day High | 26.06 |
| Day Low | 24.95 |
| 52-Week High | 40.47 |
| 52-Week Low | 14.8 |
| Volume | 693,725 |
| Average Volume | 1.38M |
| Market Cap | 1.95B |
| PE | -17.08 |
| EPS | -1.5 |
| Moving Average 50 Days | 23.67 |
| Moving Average 200 Days | 30.44 |
| Change | -0.61 |
CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
GlobeNewswire Inc.
May 15, 2025 12:00 PM GMT
IRVINE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder
SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
GlobeNewswire Inc.
May 01, 2025 12:00 PM GMT
- Award recipients Honored at the American Urological Association's 2025 Annual Meeting - - Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC - SCH
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
GlobeNewswire Inc.
Apr 26, 2025 8:10 PM GMT
- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients remained free from progression